Search Results for keywords:"National Institutes of Health"

The National Cancer Institute has announced a change in the date for a special meeting initially planned for February 24, 2025. The meeting will now take place on March 10, 2025, from 11 a.m. to 3 p.m. The format, location, and timing of the meeting will remain unchanged, and it will be conducted virtually. This meeting will be closed to the public.

The Eunice Kennedy Shriver National Institute of Child Health & Human Development announced a change to the meeting schedule of the National Advisory Board on Medical Rehabilitation Research. The meeting, which was originally planned for May 5-6, 2025, has been adjusted to a single day on May 5, 2025, from 10:00 a.m. to 5:00 p.m. The event, open to the public, will take place at 6710 B Rockledge Drive, Bethesda, MD. The change was published in the Federal Register and the notice includes a reference to the previous announcement printed on December 30, 2024.

The National Institute of General Medical Sciences is holding a special meeting to review certain grant applications. This meeting will take place virtually on July 10-11, 2025, from 10:30 a.m. to 6:30 p.m. The meeting is closed to the public to protect confidential information, such as trade secrets and personal privacy. People can reach out to Tracy Koretsky, a Scientific Review Officer, for more information via email at tracy.koretsky@nih.gov.

The National Institutes of Health (NIH) is offering a government-owned invention for licensing. This invention is a vaccine that uses a virus vector called VSV-EBOV to express the spike protein of the SARS-CoV-2 virus, which causes COVID-19. The vaccine has shown effective protection against the virus in animal tests, and it only requires a single dose. It is designed to be inexpensive to produce and provides high levels of antibodies to fight COVID-19.

The Department of Health and Human Services, specifically the National Institutes of Health (NIH), announced that certain government-owned inventions are available for licensing. One such invention involves the use of statins, like atorvastatin, to prevent hearing loss caused by chemotherapy drugs like cisplatin. Hearing loss is a common side effect for many cancer patients undergoing treatment, and statins are being explored to mitigate this issue. The announcement highlights both the potential applications for these statins in preventing hearing loss and the readiness of the technology for commercial development.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is holding a virtual meeting on April 15-16, 2021, from 9:00 a.m. to 6:00 p.m. The meeting will review and evaluate grant applications related to the Alcohol-HIV/AIDS Program Project. This meeting will be closed to the public to protect confidential information, including trade secrets and personal details of individuals associated with the applications. For more information, the contact person is Dr. Ranga Srinivas at the National Institutes of Health.

The National Institutes of Health announced a closed meeting by the National Center for Complementary and Integrative Health, which will take place virtually on March 18th-19th, 2021. This meeting is closed to the public to protect confidential information and personal privacy related to grant applications being reviewed. The purpose of the meeting is to assess and evaluate these applications related to neuroscience research on interoception. For more information, Jessica Marie McKlveen, the Scientific Review Officer, can be contacted via email.

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS), is planning to grant an exclusive license to StraightLine Bio, Inc. for certain anti-cancer inventions. These inventions involve patents related to T cell receptors targeting a cancer antigen called KK-LC-1, which is found in certain epithelial cancers. The proposed license would allow StraightLine Bio to develop and commercialize therapies using this technology worldwide, but with some specific exclusions. The public has a chance to comment or object to this plan until December 26, 2024.

The National Institute on Drug Abuse (NIDA) has announced two upcoming closed meetings. These meetings are not open to the public to protect confidential information and the privacy of individuals involved. One meeting is scheduled for May 5-6, 2025, and will focus on reviewing small business innovation research grant applications. The other is on May 5, 2025, specifically targeting time-sensitive drug abuse research grant applications. Both meetings will be held virtually.

The Eunice Kennedy Shriver National Institute of Child Health & Human Development has announced a closed meeting of the Developmental Biology Subcommittee. This meeting will take place on February 26, 2021, from 11:00 a.m. to 7:00 p.m. and will be a virtual event held at the National Institutes of Health. It will focus on reviewing and evaluating grant applications, which include confidential information like trade secrets and personal information.